Congenital myasthenic syndrome due to a genetic mutation

J Am Assoc Nurse Pract. 2023 Aug 1;35(8):519-523. doi: 10.1097/JXX.0000000000000878.


Congenital myasthenic syndrome (CMS) is a group of rare genetic disorders that mimics the symptoms of myasthenia gravis, but it is due to a genetic defect. We present a case of a male CMS patient, and the course of the disease through the years. The patient initially presented with generalized muscle weakness and difficulty swallowing. During the follow-up, he developed difficulty in chewing, bilateral external ophthalmoparesis with an almost full block of eye movements and bulbar syndrome. The case illustrates both the clinical heterogeneity and the progressive worsening of the symptoms of the disease over the years. The optimal treatment for CMS is based on the molecular defect and its localization in the neuromuscular junction. In our case, treatment with pyridostigmine resulted in good long-term control of symptoms. As a result of the patient's good compliance with treatment, he was not admitted to hospital because of respiratory distress. The lack of a unified protocol for the treatment of CMS highlights the need for a more personalized approach when dealing with patients with rare diseases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Humans
  • Male
  • Mutation / genetics
  • Myasthenia Gravis* / diagnosis
  • Myasthenic Syndromes, Congenital* / diagnosis
  • Myasthenic Syndromes, Congenital* / drug therapy
  • Myasthenic Syndromes, Congenital* / genetics
  • Pyridostigmine Bromide / therapeutic use
  • Treatment Outcome


  • Pyridostigmine Bromide